adjuvant trastuzumab did not improve outcomes for patients with her2-low breast cancer
Published 6 years ago • 198 plays • Length 7:40Download video MP4
Download video MP3
Similar videos
-
12:04
sabcs 2017: adjuvant trastuzumab did not improve outcomes for patients with her2-low breast cancer
-
5:29
adding lapatinib to adjuvant trastuzumab doesn't improve outcomes in her2-positive breast cancer
-
7:31
adding lapatinib to adjuvant trastuzumab doesn't improve outcomes in her2-positive breast cancer
-
5:46
adjuvant trastuzumab emtansine vs paclitaxel and trastuzumab for her2-positive breast cancer
-
47:29
optimizing therapy in her2 disease with dr. reshma mahtani
-
9:13
substituting trastuzumab emtansine for adjuvant trastuzumab improved idfs for breast cancer pati...
-
1:17
clinical outcomes in women with metastatic her2-low breast cancer in the real world
-
53:15
will new antibody drug conjugates cure bladder cancer?
-
6:46
a presurgery combination therapy may improve outcomes for women with her2 positive breast cancer
-
3:31
her2-low mbc patients report preserved qol with trastuzumab deruxtecan
-
6:47
extended adjuvant therapy for her2-positive early breast cancer
-
10:05
piii trial supports current standard 12-month adjuvant trastuzumab for her2-positive breast cancer
-
1:17
comment: phase 3 study shows her2 therapy clinically meaningful for metastatic breast cancer pts
-
0:56
destiny-breast04: t-dxd for patients with her2-low mbc
-
1:35:31
leveraging targeted therapies to improve outcomes across the continuum of her2 breast cancer
-
2:13
remaining questions surrounding her2-low breast cancer – how low can you go?
-
7:13
overview of the management of her2-low breast cancer patients
-
8:16
apt for her2 breast cancer patients with small tumours
-
22:50
neoadjuvant therapy for her2-positive breast cancer - dr. scott christensen